Mayo Foundation for Medical Education and Research

Myosin Therapeutics Secures $3M in Second Seed Funding to Advance Brain Cancer and Addiction Therapies

- Myosin Therapeutics has raised over $3 million in its second seed round, complementing NIH funding to advance clinical trials for glioblastoma and methamphetamine use disorder treatments. - The company's lead compound MT-125, which targets molecular nanomotors to block tumor growth, has received FDA orphan drug designation for malignant gliomas and will enter Phase 1b trials. - MT-110, the company's novel treatment for methamphetamine use disorder, is set to begin Phase 1 clinical trials, addressing a critical gap in FDA-approved treatments for this condition.